Purpose: To investigate the safety and effectiveness of the AcrySof phakic angle-supported intraocular lens (IOL) (Alcon Laboratories, Inc., Fort Worth, TX) for correction of moderate-to-high myopia in adults.
Design: One-year interim analysis of a phase 3, nonrandomized, open-label, prospective, multicenter European clinical study.
Participants: A total of 190 subjects (190 eyes) with moderate-to-high myopia. The preoperative mean manifest refraction spherical equivalent (MRSE) was -10.38 diopters (D) +/-2.43 standard deviation (SD).
Methods: Unilateral implantation of the AcrySof phakic angle-supported IOL.
Main Outcome Measures: Best spectacle-corrected visual acuity (BSCVA), uncorrected distance visual acuity (UCVA), predictability and stability of MRSE, adverse events, and endothelial cell density.
Results: Of 190 subjects enrolled, 161 completed the 1-year postoperative visit. No subjects lost > or =2 lines BSCVA. A UCVA of 20/20 or better was achieved by 57.8%; 99.4% had 20/40 or better. A BSCVA of 20/32 or better was achieved by 100% of subjects; 85.7% had 20/20 or better. The mean MRSE was -0.23 D (+/-0.50 D: -2.50 to 0.75 D). Residual refractive error was within +/-1.0 D from the target for 95.7% of subjects and within +/-0.5 D for 72.7% of subjects. The overall mean percentage change in central endothelial cell density 1 year after surgery was -4.77+/-8.04% (n = 139). No pupil ovalization, pupillary block, or retinal detachment events were observed.
Conclusions: The AcrySof phakic angle-supported IOL yielded excellent refractive correction and predictability with acceptable safety in subjects with moderate-to-high myopia. These 1-year interim analysis findings demonstrate preliminary support for the safety and efficacy of this IOL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2009.01.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Five Years Follow-Up of Acrysof Cachet® Angle-Supported Phakic Intraocular Lens Implantation for Myopia Correction.
J Ophthalmol
March 2022
Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, Mainz 55131, Germany.
Purpose: The Acrysof Cachet® angle-supported phakic intraocular lens (pIOL) (Alcon Laboratories, Inc., Fort Worth, TX) is designed to correct high refractive errors in human eyes. The aim of this study was to evaluate the outcome of AcrySof Cachet® angle-supported pIOL implantation with particular regard to efficacy and safety of the implant over a 60-month follow-up period.
View Article and Find Full Text PDFAxial Length Change in Pseudophakic Eyes Measured by IOLMaster 700.
Transl Vis Sci Technol
May 2021
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China.
Purpose: The purpose of this study was to investigate the change in axial length (AL) after cataract surgery measured by swept source optical coherence tomography (IOLMaster 700), and explore ways to eliminate this AL measurement error in pseudophakic eyes.
Methods: Patients with cataract who underwent unilateral phacoemulsification with four types of intraocular lens (IOLs) implantation (Asphina 509M, Tecnis PCB00, enVista MX60, and Acrysof SN60WF) were enrolled. Bilateral AL measurements were performed before and 1 month after cataract surgery utilizing IOLMaster 700.
Ten-year safety follow-up and post-explant analysis of an anterior chamber phakic IOL.
J Cataract Refract Surg
November 2020
From the Department of Ophthalmology, Goethe-University (Kohnen), Frankfurt, Germany; California Eye Institute (Maxwell), Fresno, California, USA; Department of Ophthalmology, University of British Columbia (Holland), Vancouver, Pacific Laser Eye Centre (Holland), Vancouver, British Columbia, Canada; Associated Eye Care, University of Minnesota (Lane), Stillwater, Minnesota, and Alcon Research LLC (Lane, Von Tress, Salem, LaFontaine), Fort Worth, Texas, USA.
Purpose: To assess endothelial cell loss (ECL) rate and collect safety data in patients with AcrySof L-series Cachet phakic intraocular lens (pIOL) up to 10 years post-implantation.
Setting: Clinical settings in the United States, European Union, and Canada.
Design: Nonrandomized, observational, open-label safety study.
Clinical outcomes with a diffractive trifocal intraocular lens.
Eur J Ophthalmol
July 2018
1 Vissum Ophthalmological Corporation, Alicante, Spain.
Purpose: To evaluate clinical and visual outcomes, quality of near vision, and intraocular optical quality of patients bilaterally implanted with a trifocal PanOptix intraocular lens.
Methods: In this prospective consecutive case-series study, 52 eyes of 26 bilateral patients (mean age, 60.2 ± 7.
Femtosecond laser-assisted cataract surgery in eyes with foldable anterior or posterior chamber phakic intraocular lenses.
J Cataract Refract Surg
February 2018
From the Department of Ophthalmology (Kohnen, Steinwender), Goethe University, Frankfurt, Germany; the Department of Ophthalmology (Steinwender), Medical University of Graz, Graz, Austria.
We describe a technique for the application of femtosecond laser-assisted cataract surgery in eyes with cataract and previous implantation of a foldable anterior or posterior chamber phakic intraocular lens (pIOL). In 2 eyes with an anterior chamber pIOL (angle-supported Acrysof Cachet) and 3 eyes with a posterior chamber pIOL (2 eyes with an Implantable Collamer Lens pIOL; 1 eye with a Phakic Refractive Lens), a femtosecond laser was used to create a capsulotomy, perform lens fragmentation, and create corneal incisions with the pIOL in situ. In all cases, the capsulotomy was created successfully.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!